146 related articles for article (PubMed ID: 26300269)
1. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome.
Margusino-Framiñán L; Pertega-Diaz S; Pena-Bello L; Sangiao-Alvarellos S; Outeiriño-Blanco E; Pita-Gutierrez F; Pita-Fernandez S; Cordido F
Eur J Intern Med; 2015 Nov; 26(9):736-41. PubMed ID: 26300269
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976
[No Abstract] [Full Text] [Related]
3. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.
Orlewska E; Stępień R; Orlewska K
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):15-25. PubMed ID: 30122081
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.
Brue T; Chanson P; Rodien P; Delemer B; Drui D; Marié L; Juban L; Salvi L; Henocque R; Raverot G
Front Endocrinol (Lausanne); 2021; 12():745843. PubMed ID: 34690933
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiology of acromegaly in Spain].
Sesmilo G
Endocrinol Nutr; 2013 Oct; 60(8):470-4. PubMed ID: 23246411
[TBL] [Abstract][Full Text] [Related]
7. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
8. The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly.
Polat Korkmaz O; Gurcan M; Nuhoglu Kantarci FE; Haliloglu O; Ozkaya HM; Sahin S; Oren MM; Tanriover N; Gazioglu N; Kadioglu P
Pituitary; 2019 Aug; 22(4):387-396. PubMed ID: 31098838
[TBL] [Abstract][Full Text] [Related]
9. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis.
Pita-Gutierrez F; Pertega-Diaz S; Pita-Fernandez S; Pena L; Lugo G; Sangiao-Alvarellos S; Cordido F
PLoS One; 2013; 8(4):e61523. PubMed ID: 23634209
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
11. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
12. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.
Sesmilo G; Resmini E; Bernabeu I; Aller J; Soto A; Mora M; Picó A; Fajardo C; Torres E; Alvarez-Escolá C; García R; Blanco C; Cámara R; Gaztambide S; Salinas I; Pozo CD; Castells I; Villabona C; Biagetti B; Webb SM
Clin Endocrinol (Oxf); 2014 Dec; 81(6):883-90. PubMed ID: 24612232
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis.
Leonart LP; Riveros BS; Krahn MD; Pontarolo R
Neuroendocrinology; 2021; 111(4):388-402. PubMed ID: 32299084
[TBL] [Abstract][Full Text] [Related]
14. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
15. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
Zhang L; Wu X; Yan Y; Qian J; Lu Y; Luo C
Brain Dev; 2015 Feb; 37(2):181-90. PubMed ID: 24815226
[TBL] [Abstract][Full Text] [Related]
16. Pegvisomant and improvement of quality of life in acromegalic patients.
Neggers SJ; van der Lely AJ
Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
18. [Advances in the treatment of acromegaly].
Krysiak R; Okopień B; Marek B
Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
[TBL] [Abstract][Full Text] [Related]
19. [Acromegaly: new principles for treatment].
Jørgensen JO; Feldt-Rasmussen UF; Andersen M; Kristensen LØ; Laurberg P; Weeke J
Ugeskr Laeger; 2007 Mar; 169(10):904-6. PubMed ID: 17359733
[TBL] [Abstract][Full Text] [Related]
20. Role of medical therapy in the management of acromegaly.
Vance ML; Laws ER
Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]